BCR‐ABL1‐positive and JAK2 V617F‐positive clones in 23 patients with both aberrations reveal biologic and clinical importance
- 5 February 2016
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 176 (1) , 135-139
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Concomitant occurrence of BCR-ABL and JAK2V617F mutationBlood, 2011
- JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disordersLeukemia, 2008
- Chronic myeloproliferative diseases with concurrent BCR–ABL junction and JAK2V617F mutationLeukemia, 2007
- Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosisLeukemia, 2007
- Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutationBlood, 2007
- Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627ELeukemia, 2006
- Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangementCancer Genetics and Cytogenetics, 2006
- The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disordersBlood, 2005
- The Philadelphia translocation and pre‐existing myeloproliferative disordersBritish Journal of Haematology, 2005